Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lovenox Clear all
Completed Phase 4 Interventional Results available

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

NCT04367831
View directory record Official record
Conditions
COVID-19, Venous Thromboses, Arterial Thrombosis
Interventions
Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC, Enoxaparin/Lovenox Intermediate Dose
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 25, 2026, 11:38 AM EDT
Withdrawn Phase 2 Interventional

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

NCT00723658
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 25, 2026, 11:38 AM EDT
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 25, 2026, 11:38 AM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Covid-19 Associated Coagulopathy

NCT04360824
View directory record Official record
Conditions
COVID 19 Associated Coagulopathy
Interventions
Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Iowa City, Iowa • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

NCT02072434
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Edoxaban, Warfarin, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

NCT00113932
View directory record Official record
Conditions
Multiple Myeloma
Interventions
High-Dose Density Therapy
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 25, 2026, 11:38 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 25, 2026, 11:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

NCT00093158
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2007 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 25, 2026, 11:38 AM EDT
Not listed No phase listed Observational

Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma

NCT06025162
View directory record Official record
Conditions
Thromboembolism, Venous
Interventions
enoxaparin
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Not applicable Interventional

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin

NCT00321009
View directory record Official record
Conditions
Coronary Artery Disease, Acute Myocardial Infarction
Interventions
Enoxaparin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 4 Interventional

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement

NCT00298285
View directory record Official record
Conditions
Mechanical Valve Replacement, Warfarin Therapy
Interventions
enoxaparin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Sep 25, 2026, 11:38 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

NCT02744833
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
GMI-1271, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 25, 2026, 11:38 AM EDT
Completed No phase listed Observational

Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women With Prosthetic Heart Valves

NCT00329290
View directory record Official record
Conditions
Pregnancy, Anticoagulation, Prosthetic Heart Valves
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

NCT00077792
View directory record Official record
Conditions
Myocardial Infarction, Acute ST-Segment Elevation
Interventions
Enoxaparin sodium (XRP4563)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
20,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2009 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

NCT00329628
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 25, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT06118957
View directory record Official record
Conditions
Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 25, 2026, 11:38 AM EDT